Loading
A phase 3 trial of Cisplatin in advanced solid tumours, run by Jiangsu Simcere Pharmaceutical Co., Ltd., active and no longer recruiting.
A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions is a phase 3 interventional study registered as NCT04914598 by Jiangsu Simcere Pharmaceutical Co., Ltd., with 290 participants enrolled, started 2021-07-28 and due to reach its primary completion in 2025-02-10. Interventions recorded: ENDOSTAR，cisplatin and Placebo , cisplatin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Simcere Pharmaceutical and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/